AGÕæÈ˹ٷ½

STOCK TITAN

[SC 14D9/A] GMS Inc. Amended Tender Offer Recommendation

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SC 14D9/A
Rhea-AI Filing Summary

Nutriband Inc. (Nasdaq: NTRB) filed a Form 8-K announcing two capital-structure actions.

Item 3.02 � Unregistered Sales: On 5 Aug 2025 the company issued a stock dividend of 3,008,643 non-voting Series A Convertible Preferred shares to shareholders of record as of 25 Jul 2025, at one preferred share for every four common shares. Fractional shares were rounded down. The shares are restricted and held by Equinity Trust until they become convertible and are registered for trading.

Item 5.03 � Charter Amendment: The Board, acting under Nevada law without shareholder approval, created the Series A class on 9 Jul 2025 and later increased the authorization to 10 million shares via a Certificate of Correction filed 21 Jul 2025. Each Series A share will convert 1-for-1 into common stock only after FDA approval of AVERSA-based transdermal products. Preferred holders are entitled to any dividends declared on either the preferred or common classes.

The dividend rewards current shareholders but, if fully issued and converted, could significantly expand the common share base once regulatory milestones are achieved.

Nutriband Inc. (Nasdaq: NTRB) ha presentato un modulo 8-K annunciando due azioni relative alla struttura del capitale.

Voce 3.02 � Vendite non registrate: Il 5 agosto 2025 la società ha emesso un dividendo azionario di 3.008.643 azioni privilegiate convertibili di Serie A senza diritto di voto ai soci registrati al 25 luglio 2025, con un’azione privilegiata ogni quattro azioni ordinarie. Le frazioni di azioni sono state arrotondate per difetto. Le azioni sono vincolate e detenute da Equinity Trust fino a quando non diventeranno convertibili e registrate per la negoziazione.

Voce 5.03 � Modifica dello statuto: Il Consiglio, agendo secondo la legge del Nevada senza l’approvazione degli azionisti, ha creato la classe Serie A il 9 luglio 2025 e successivamente ha aumentato l’autorizzazione a 10 milioni di azioni tramite un Certificato di Correzione depositato il 21 luglio 2025. Ogni azione di Serie A sarà convertita 1 a 1 in azioni ordinarie solo dopo l’approvazione FDA dei prodotti transdermici basati su AVERSA. I detentori delle azioni privilegiate hanno diritto a qualsiasi dividendo dichiarato sia sulle azioni privilegiate sia su quelle ordinarie.

Il dividendo premia gli azionisti attuali ma, se completamente emesso e convertito, potrebbe aumentare significativamente la base delle azioni ordinarie una volta raggiunti i traguardi regolatori.

Nutriband Inc. (Nasdaq: NTRB) presentó un Formulario 8-K anunciando dos acciones relacionadas con la estructura de capital.

Punto 3.02 � Ventas no registradas: El 5 de agosto de 2025, la compañía emitió un dividendo en acciones de 3.008.643 acciones preferentes convertibles Serie A sin derecho a voto a los accionistas registrados al 25 de julio de 2025, a razón de una acción preferente por cada cuatro acciones comunes. Las fracciones de acciones se redondearon hacia abajo. Las acciones están restringidas y son custodiadas por Equinity Trust hasta que se vuelvan convertibles y se registren para su negociación.

Punto 5.03 � Enmienda del estatuto: La Junta, actuando bajo la ley de Nevada sin la aprobación de los accionistas, creó la clase Serie A el 9 de julio de 2025 y posteriormente aumentó la autorización a 10 millones de acciones mediante un Certificado de Corrección presentado el 21 de julio de 2025. Cada acción Serie A se convertirá 1 a 1 en acciones comunes solo después de la aprobación de la FDA de los productos transdérmicos basados en AVERSA. Los tenedores de acciones preferentes tienen derecho a cualquier dividendo declarado sobre las clases preferente o común.

El dividendo recompensa a los accionistas actuales pero, si se emite y convierte completamente, podría expandir significativamente la base de acciones comunes una vez que se logren los hitos regulatorios.

Nutriband Inc. (나스ë‹�: NTRB)ëŠ� ìžë³¸ 구조 ê´€ë � ë‘� 가지 조치ë¥� 발표하는 Form 8-Kë¥� 제출했습니다.

항목 3.02 â€� 비등ë¡� íŒë§¤: 2025ë…� 8ì›� 5ì� 회사ëŠ� 2025ë…� 7ì›� 25ì� 기준 주주들ì—ê²� ì˜ê²°ê¶� 없는 시리ì¦� A 전환 ìš°ì„ ì£� 3,008,643ì£�ë¥� 보통ì£� 4주당 ìš°ì„ ì£� 1ì£� 비율ë¡� 배당했습니다. 소수 주ì‹ì€ 내림 처리ë˜ì—ˆìŠµë‹ˆë‹�. 해당 주ì‹ì€ 제한 주ì‹ìœ¼ë¡œ, 전환 가능해지ê³� 거래 등ë¡ë� 때까지 Equinity Trustê°€ 보유합니ë‹�.

항목 5.03 â€� ì •ê´€ 수정: ì´ì‚¬íšŒëŠ” 네바ë‹� ë²•ì— ë”°ë¼ ì£¼ì£¼ ìŠ¹ì¸ ì—†ì´ 2025ë…� 7ì›� 9ì� 시리ì¦� A í´ëž˜ìŠ¤ë¥¼ 신설하고, 2025ë…� 7ì›� 21ì� 수정 ì¦ëª…ì„� 제출ì� 통해 허가 주ì‹ì� 1,000ë§� ì£�ë¡� ì¦ëŒ€í–ˆìŠµë‹ˆë‹¤. ê°� 시리ì¦� A 주ì‹ì€ AVERSA 기반 경피 제품ì—� 대í•� FDA 승ì¸ì� 완료ë� 후ì—ë§� 1대1ë¡� 보통주로 전환ë©ë‹ˆë‹�. ìš°ì„ ì£� 보유ìžëŠ” ìš°ì„ ì£� ë˜ëŠ” ë³´í†µì£¼ì— ì„ ì–¸ë� ë°°ë‹¹ê¸ˆì„ ë°›ì„ ê¶Œë¦¬ê°€ 있습니다.

ì´ë²ˆ ë°°ë‹¹ì€ í˜„ìž¬ 주주ì—게 ë³´ìƒì� 제공하지ë§�, 전량 발행 ë°� 전환 ì‹� 규제 ìŠ¹ì¸ ë‹¬ì„± í›� 보통ì£� 기반ì� í¬ê²Œ 확대í•� ìˆ� 있습니다.

Nutriband Inc. (Nasdaq : NTRB) a déposé un formulaire 8-K annonçant deux actions relatives à la structure du capital.

Point 3.02 � Ventes non enregistrées : Le 5 août 2025, la société a émis un dividende en actions de 3 008 643 actions privilégiées convertibles de série A sans droit de vote aux actionnaires inscrits au 25 juillet 2025, à raison d’une action privilégiée pour quatre actions ordinaires. Les fractions d’actions ont été arrondies à la baisse. Les actions sont restreintes et détenues par Equinity Trust jusqu’� ce qu’elles deviennent convertibles et soient enregistrées pour la négociation.

Point 5.03 � Modification des statuts : Le conseil d’administration, agissant en vertu de la loi du Nevada sans approbation des actionnaires, a créé la classe Série A le 9 juillet 2025 et a ensuite augmenté l’autorisation à 10 millions d’actions via un certificat de correction déposé le 21 juillet 2025. Chaque action de la série A sera convertie en actions ordinaires au ratio 1 pour 1 uniquement après l’approbation de la FDA des produits transdermiques à base d’AVERSA. Les détenteurs d’actions privilégiées ont droit à tout dividende déclaré sur les classes privilégiées ou ordinaires.

Le dividende récompense les actionnaires actuels mais, s’il est entièrement émis et converti, pourrait considérablement augmenter le nombre d’actions ordinaires une fois les étapes réglementaires franchies.

Nutriband Inc. (Nasdaq: NTRB) hat ein Formular 8-K eingereicht, in dem zwei Maßnahmen zur Kapitalstruktur angekündigt wurden.

Posten 3.02 â€� Nicht registrierte Verkäufe: Am 5. August 2025 gab das Unternehmen eine Aktien-Dividende von 3.008.643 stimmlosen Series A wandelbaren Vorzugsaktien an die zum 25. Juli 2025 eingetragenen Aktionäre aus, im Verhältnis von einer Vorzugsaktie für je vier Stammaktien. Bruchteile von Aktien wurden abgerundet. Die Aktien sind ±ð¾±²Ô²µ±ð²õ³¦³ó°ùä²Ô°ì³Ù und werden von Equinity Trust gehalten, bis sie wandelbar werden und für den Handel registriert sind.

Posten 5.03 � Satzungsänderung: Der Vorstand hat nach Nevada-Recht ohne Zustimmung der Aktionäre am 9. Juli 2025 die Serie A geschaffen und die Genehmigung später durch eine am 21. Juli 2025 eingereichte Korrektururkunde auf 10 Millionen Aktien erhöht. Jede Serie A-Aktie wird erst nach FDA-Zulassung von AVERSA-basierten transdermalen Produkten 1:1 in Stammaktien umgewandelt. Vorzugsaktionäre haben Anspruch auf Dividenden, die entweder für Vorzugs- oder Stammaktien erklärt werden.

Die Dividende belohnt die aktuellen Aktionäre, könnte aber bei vollständiger Ausgabe und Umwandlung die Anzahl der Stammaktien nach Erreichen regulatorischer Meilensteine erheblich erhöhen.

Positive
  • 3,008,643 Series A Preferred shares issued as a free dividend, giving existing holders upside linked to FDA approval.
  • Conversion is contingent on regulatory success, aligning potential dilution with a value-creating milestone.
Negative
  • Authorization of up to 10 million convertible preferred shares introduces substantial future dilution risk once conditions are met.
  • Series A class was created and issued without shareholder approval, raising possible governance concerns.

Insights

TL;DR: Dividend grants optionality now, but authorizing 10 M convertible preferred sets stage for post-FDA dilution; overall neutral impact.

The 3.0 M Series A shares distributed at no cost immediately enhance shareholder upside should AVERSA products secure FDA approval. Conversion is conditional, so no dilution occurs until a value-creating catalyst materialises. However, expanding the authorization to 10 M shares raises the ceiling for future dilution and signals management’s intent to preserve financing flexibility. Because the Board acted without a shareholder vote, governance-focused investors may scrutinise the move. Near-term cash flows remain unchanged; impact hinges entirely on regulatory outcomes, keeping the news fundamentally neutral at this stage.

Nutriband Inc. (Nasdaq: NTRB) ha presentato un modulo 8-K annunciando due azioni relative alla struttura del capitale.

Voce 3.02 � Vendite non registrate: Il 5 agosto 2025 la società ha emesso un dividendo azionario di 3.008.643 azioni privilegiate convertibili di Serie A senza diritto di voto ai soci registrati al 25 luglio 2025, con un’azione privilegiata ogni quattro azioni ordinarie. Le frazioni di azioni sono state arrotondate per difetto. Le azioni sono vincolate e detenute da Equinity Trust fino a quando non diventeranno convertibili e registrate per la negoziazione.

Voce 5.03 � Modifica dello statuto: Il Consiglio, agendo secondo la legge del Nevada senza l’approvazione degli azionisti, ha creato la classe Serie A il 9 luglio 2025 e successivamente ha aumentato l’autorizzazione a 10 milioni di azioni tramite un Certificato di Correzione depositato il 21 luglio 2025. Ogni azione di Serie A sarà convertita 1 a 1 in azioni ordinarie solo dopo l’approvazione FDA dei prodotti transdermici basati su AVERSA. I detentori delle azioni privilegiate hanno diritto a qualsiasi dividendo dichiarato sia sulle azioni privilegiate sia su quelle ordinarie.

Il dividendo premia gli azionisti attuali ma, se completamente emesso e convertito, potrebbe aumentare significativamente la base delle azioni ordinarie una volta raggiunti i traguardi regolatori.

Nutriband Inc. (Nasdaq: NTRB) presentó un Formulario 8-K anunciando dos acciones relacionadas con la estructura de capital.

Punto 3.02 � Ventas no registradas: El 5 de agosto de 2025, la compañía emitió un dividendo en acciones de 3.008.643 acciones preferentes convertibles Serie A sin derecho a voto a los accionistas registrados al 25 de julio de 2025, a razón de una acción preferente por cada cuatro acciones comunes. Las fracciones de acciones se redondearon hacia abajo. Las acciones están restringidas y son custodiadas por Equinity Trust hasta que se vuelvan convertibles y se registren para su negociación.

Punto 5.03 � Enmienda del estatuto: La Junta, actuando bajo la ley de Nevada sin la aprobación de los accionistas, creó la clase Serie A el 9 de julio de 2025 y posteriormente aumentó la autorización a 10 millones de acciones mediante un Certificado de Corrección presentado el 21 de julio de 2025. Cada acción Serie A se convertirá 1 a 1 en acciones comunes solo después de la aprobación de la FDA de los productos transdérmicos basados en AVERSA. Los tenedores de acciones preferentes tienen derecho a cualquier dividendo declarado sobre las clases preferente o común.

El dividendo recompensa a los accionistas actuales pero, si se emite y convierte completamente, podría expandir significativamente la base de acciones comunes una vez que se logren los hitos regulatorios.

Nutriband Inc. (나스ë‹�: NTRB)ëŠ� ìžë³¸ 구조 ê´€ë � ë‘� 가지 조치ë¥� 발표하는 Form 8-Kë¥� 제출했습니다.

항목 3.02 â€� 비등ë¡� íŒë§¤: 2025ë…� 8ì›� 5ì� 회사ëŠ� 2025ë…� 7ì›� 25ì� 기준 주주들ì—ê²� ì˜ê²°ê¶� 없는 시리ì¦� A 전환 ìš°ì„ ì£� 3,008,643ì£�ë¥� 보통ì£� 4주당 ìš°ì„ ì£� 1ì£� 비율ë¡� 배당했습니다. 소수 주ì‹ì€ 내림 처리ë˜ì—ˆìŠµë‹ˆë‹�. 해당 주ì‹ì€ 제한 주ì‹ìœ¼ë¡œ, 전환 가능해지ê³� 거래 등ë¡ë� 때까지 Equinity Trustê°€ 보유합니ë‹�.

항목 5.03 â€� ì •ê´€ 수정: ì´ì‚¬íšŒëŠ” 네바ë‹� ë²•ì— ë”°ë¼ ì£¼ì£¼ ìŠ¹ì¸ ì—†ì´ 2025ë…� 7ì›� 9ì� 시리ì¦� A í´ëž˜ìŠ¤ë¥¼ 신설하고, 2025ë…� 7ì›� 21ì� 수정 ì¦ëª…ì„� 제출ì� 통해 허가 주ì‹ì� 1,000ë§� ì£�ë¡� ì¦ëŒ€í–ˆìŠµë‹ˆë‹¤. ê°� 시리ì¦� A 주ì‹ì€ AVERSA 기반 경피 제품ì—� 대í•� FDA 승ì¸ì� 완료ë� 후ì—ë§� 1대1ë¡� 보통주로 전환ë©ë‹ˆë‹�. ìš°ì„ ì£� 보유ìžëŠ” ìš°ì„ ì£� ë˜ëŠ” ë³´í†µì£¼ì— ì„ ì–¸ë� ë°°ë‹¹ê¸ˆì„ ë°›ì„ ê¶Œë¦¬ê°€ 있습니다.

ì´ë²ˆ ë°°ë‹¹ì€ í˜„ìž¬ 주주ì—게 ë³´ìƒì� 제공하지ë§�, 전량 발행 ë°� 전환 ì‹� 규제 ìŠ¹ì¸ ë‹¬ì„± í›� 보통ì£� 기반ì� í¬ê²Œ 확대í•� ìˆ� 있습니다.

Nutriband Inc. (Nasdaq : NTRB) a déposé un formulaire 8-K annonçant deux actions relatives à la structure du capital.

Point 3.02 � Ventes non enregistrées : Le 5 août 2025, la société a émis un dividende en actions de 3 008 643 actions privilégiées convertibles de série A sans droit de vote aux actionnaires inscrits au 25 juillet 2025, à raison d’une action privilégiée pour quatre actions ordinaires. Les fractions d’actions ont été arrondies à la baisse. Les actions sont restreintes et détenues par Equinity Trust jusqu’� ce qu’elles deviennent convertibles et soient enregistrées pour la négociation.

Point 5.03 � Modification des statuts : Le conseil d’administration, agissant en vertu de la loi du Nevada sans approbation des actionnaires, a créé la classe Série A le 9 juillet 2025 et a ensuite augmenté l’autorisation à 10 millions d’actions via un certificat de correction déposé le 21 juillet 2025. Chaque action de la série A sera convertie en actions ordinaires au ratio 1 pour 1 uniquement après l’approbation de la FDA des produits transdermiques à base d’AVERSA. Les détenteurs d’actions privilégiées ont droit à tout dividende déclaré sur les classes privilégiées ou ordinaires.

Le dividende récompense les actionnaires actuels mais, s’il est entièrement émis et converti, pourrait considérablement augmenter le nombre d’actions ordinaires une fois les étapes réglementaires franchies.

Nutriband Inc. (Nasdaq: NTRB) hat ein Formular 8-K eingereicht, in dem zwei Maßnahmen zur Kapitalstruktur angekündigt wurden.

Posten 3.02 â€� Nicht registrierte Verkäufe: Am 5. August 2025 gab das Unternehmen eine Aktien-Dividende von 3.008.643 stimmlosen Series A wandelbaren Vorzugsaktien an die zum 25. Juli 2025 eingetragenen Aktionäre aus, im Verhältnis von einer Vorzugsaktie für je vier Stammaktien. Bruchteile von Aktien wurden abgerundet. Die Aktien sind ±ð¾±²Ô²µ±ð²õ³¦³ó°ùä²Ô°ì³Ù und werden von Equinity Trust gehalten, bis sie wandelbar werden und für den Handel registriert sind.

Posten 5.03 � Satzungsänderung: Der Vorstand hat nach Nevada-Recht ohne Zustimmung der Aktionäre am 9. Juli 2025 die Serie A geschaffen und die Genehmigung später durch eine am 21. Juli 2025 eingereichte Korrektururkunde auf 10 Millionen Aktien erhöht. Jede Serie A-Aktie wird erst nach FDA-Zulassung von AVERSA-basierten transdermalen Produkten 1:1 in Stammaktien umgewandelt. Vorzugsaktionäre haben Anspruch auf Dividenden, die entweder für Vorzugs- oder Stammaktien erklärt werden.

Die Dividende belohnt die aktuellen Aktionäre, könnte aber bei vollständiger Ausgabe und Umwandlung die Anzahl der Stammaktien nach Erreichen regulatorischer Meilensteine erheblich erhöhen.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14D-9

(RULE 14d-101)

 

(Amendment No. 1)

 

SOLICITATION/RECOMMENDATION STATEMENT

UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

 

GMS INC.

(Name of Subject Company)

 

GMS INC.

(Name of Persons Filing Statement)

 

Common stock, par value $0.01 per share

(Title of Class of Securities)

 

36251C103

(CUSIP Number of Class of Securities)

 

Craig Apolinsky
Senior Vice President and General Counsel
115 Perimeter Center Place, Suite 600
Atlanta, Georgia 30346
(800) 392-4619

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person(s) Filing Statement)

 

Copy to:

W. Scott Ortwein
Justin R. Howard
Kyle G. Healy
Alston & Bird LLP
1201 West Peachtree Street
Atlanta, Georgia 30309
(404) 881-7000

 

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

 

 

 

 

 

This Amendment No. 1 (this “Amendment”) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (the “Schedule 14D-9”) filed by GMS Inc., a Delaware corporation (“GMS” or the “company”) with the Securities and Exchange Commission on July 14, 2025, relating to the tender offer by The Home Depot, Inc., a Delaware corporation (“The Home Depot”), and Gold Acquisition Sub, Inc., a Delaware corporation and an indirect, wholly owned subsidiary of The Home Depot (“Purchaser”), to purchase all outstanding shares of common stock, par value $0.01 per share (the “Shares”) of GMS, at a purchase price of $110.00 per Share in cash, subject to any required withholding of taxes, on the terms and subject to the conditions set forth in the Offer to Purchase, dated July 14, 2025 (as amended or supplemented from time to time) (the “Offer to Purchase”), and in the related Letter of Transmittal (as amended or supplemented from time to time) (the “Letter of Transmittal” and, together with the Offer to Purchase, the “Offer”).

 

Capitalized terms used but not otherwise defined in this Amendment shall have the meanings ascribed to them in the Schedule 14D-9. Except as set forth below, the information set forth in the Schedule 14D-9 remains unchanged and is incorporated herein by reference as relevant to the items in this Amendment.

 

ITEM 2. IDENTITY AND BACKGROUND OF FILING PERSON

 

Item 2 of the Schedule 14D-9 is hereby amended and supplemented as follows:

 

The seventh paragraph of the section entitled “Tender Offer” is hereby amended and supplemented by replacing the second sentence of the paragraph with the following sentence:

 

“On August 7, 2025, in connection with The Home Depot’s voluntary withdrawal and refiling of its Premerger Notification and Report Form under the HSR Act, Purchaser extended the Offer. The Offer was previously scheduled to expire at one minute after 11:59 P.M., Eastern Time, on August 8, 2025. The expiration time of the Offer is extended to one minute after 11:59 P.M., Eastern Time, on August 22, 2025 (unless Purchaser shall have extended the period during which the Offer is open in accordance with the merger agreement, in which event the “Expiration Time” will mean the last time and date at which the Offer, as so extended by Purchaser, will expire).”

 

ITEM 8. ADDITIONAL INFORMATION

 

Item 8 of the Schedule 14D-9 is hereby amended and supplemented as follows:

 

1.The following is hereby added immediately prior to the section entitled “Regulatory Approvals”:

 

Legal Proceedings

 

Beginning on July 16, 2025, alleged GMS stockholders filed two complaints in the Supreme Court of the State of New York County of New York, captioned Wright v. GMS Inc., et al., No. 654243/2025 (N.Y. Sup. Ct. filed on July 16, 2025) and Malone v. GMS Inc., et al., No. 654271/2025 (N.Y. Sup. Ct. filed on July 17, 2025). The complaints, each filed as an individual action, name GMS, its directors, and its chief executive officer as defendants and generally allege claims of negligent misrepresentation and concealment and negligence related to alleged disclosure deficiencies, in violation of New York common law, with respect to the Schedule 14D-9 filed with the SEC in connection with the Offer and Merger, and seek to enjoin the Merger, as well as damages, costs and attorneys’ and experts’ fees. As of July 31, 2025, GMS has also received demand letters from several purported stockholders related to alleged disclosure deficiencies in the Schedule 14D-9. The defendants, including GMS, believe that the claims asserted in these lawsuits and demand letters are without merit. Nonetheless, no assurances can be made as to the outcome of such actions or demands.”

 

 

 

 

2.The second paragraph of the subsection entitled “Compliance with HSR Act” under the section entitled “Regulatory Approvals” is hereby amended and supplemented by replacing the second and third sentences of the paragraph with the following sentences:

 

“Each of The Home Depot and the company filed a Premerger Notification and Report Form under the HSR Act with respect to the Offer and the Merger with the Antitrust Division and the FTC on July 21, 2025. On August 5, 2025, The Home Depot voluntarily withdrew its Premerger Notification and Report Form under the HSR Act relating to the Purchaser’s proposed acquisition of the company in order to provide the Antitrust Division with additional time to review the proposed acquisition and information recently provided to them. The Home Depot then refiled its Premerger Notification and Report Form with the Antitrust Division and the DOJ on August 7, 2025. As a result, the required waiting period with respect to the Offer will expire in the ordinary course at 11:59 P.M., Eastern Time, on August 22, 2025, fifteen (15) calendar days from the date of such filing, unless (i) earlier terminated by the FTC and the Antitrust Division, (ii) the FTC or the Antitrust Division issues a request for additional information and documentary material (a “Second Request”) prior to that time, or (iii) The Home Depot withdraws its HSR Premerger Notification and Report Form.”

 

3.The subsection entitled “Canada Competition Act ” under the section entitled “Regulatory Approvals” is hereby amended and supplemented by adding the following at the end of the first paragraph of such subsection:

 

“On July 22, 2025, The Home Depot submitted a request for an ARC or a “no-action” letter to the Commissioner. Additionally, the parties have filed pre-merger notification materials with the Commissioner, which were certified as complete by the Canadian Competition Bureau as of August 6, 2025.”

 

ITEM 9. EXHIBITS

 

Item 9 of the Schedule 14D-9 is hereby amended and supplemented by adding the following exhibits:

 

Exhibit No.   Description
(a)(5)(I)  

Press Release issued by The Home Depot, dated August 7, 2025 (incorporated by reference to Exhibit (a)(5)(A) to the Schedule TO filed by Purchaser and The Home Depot on August 7, 2025).

 

 

 

 

SIGNATURE

 

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  GMS INC.
   
  By: /s/ Scott M. Deakin
    Name: Scott M. Deakin
    Title: Chief Financial Officer

 

Date: August 7, 2025

 

 

 

 

FAQ

What event did Nutriband (NTRB) report in its 8-K dated 5 Aug 2025?

The company disclosed a stock dividend of 3,008,643 Series A Preferred shares and an amendment authorizing up to 10 M such shares.

How many Series A Preferred shares were distributed to shareholders?

3,008,643 shares, issued at a rate of one preferred for every four common shares.

When can the Series A Preferred convert into common stock?

Each share becomes convertible 1-for-1 after FDA approval of AVERSA-based transdermal products.

Are the Series A Preferred shares currently tradeable?

No. They are restricted and held by Equinity Trust until conversion eligibility and SEC registration are completed.

How many Series A Preferred shares are now authorized?

The Board increased the authorization to 10,000,000 shares via a Certificate of Correction filed 21 Jul 2025.

Did shareholders vote on creating the Series A Preferred class?

No. The Board approved the amendment without shareholder action under Nevada statute 78.315.
Gms Inc

NYSE:GMS

GMS Rankings

GMS Latest News

GMS Latest SEC Filings

GMS Stock Data

4.17B
37.78M
0.7%
107.59%
3.18%
Building Products & Equipment
Wholesale-lumber & Other Construction Materials
United States
TUCKER